Dizal Pharmaceuticals
Clinical trials sponsored by Dizal Pharmaceuticals, explained in plain language.
-
New drug duo targets tough lung cancer in patients out of options
Disease control Recruiting nowThis study is testing whether two experimental drugs, DZD9008 and AZD4205, are safe and can help control advanced non-small cell lung cancer in patients with specific genetic changes (EGFR mutations). It is for people whose cancer has continued to grow despite receiving standard …
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug enters first human trials for Tough-to-Treat lung cancer
Disease control Recruiting nowThis is the first time researchers are testing the experimental drug DZD6008 in people. The study aims to find a safe dose and see if it can shrink tumors in adults with advanced non-small cell lung cancer that has a specific genetic change called an EGFR mutation. The trial will…
Phase: PHASE1 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug trial seeks to control advanced lung cancer in patients who have run out of options
Disease control Recruiting nowThis is the first study in people to test a new drug called DZD6008 for advanced non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutations). The main goals are to find a safe dose and see if the drug can shrink tumors. It will enroll about 140 adults wh…
Phase: PHASE1 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug trial offers hope for advanced cancer patients
Disease control Recruiting nowThis early-stage study is testing a new drug called GW5282 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Researchers will first test increasing doses to check…
Phase: PHASE1, PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for lymphoma patients Who've run out of options
Disease control Recruiting nowThis study is testing whether an experimental drug called golidocitinib works better than standard treatments for adults with peripheral T-cell lymphoma that has returned or stopped responding to previous therapies. Researchers will compare how long patients live without their ca…
Phase: PHASE3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New pill tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing an experimental pill called DZD8586 for adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back or stopped responding to prior treatments. Researchers want to see if the drug can shrink tumors and understand what side effects pa…
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New drug trial offers hope for patients with stubborn blood disorder
Disease control Recruiting nowThis study is testing whether an experimental drug called DZD8586 can safely increase platelet counts in adults with immune thrombocytopenia (ITP) who haven't responded well to standard treatments. The trial will enroll 60 participants who will receive different doses of the medi…
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Mar 02, 2026 15:28 UTC